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NF-kB protects malignant cells from death and therefore it was considered as a cancer treatment target.
However, systemic NF-kB inhibition resulted in inflammation and other undesired outcomes. In this issue
of Cancer Cell, Tornatore and colleagues solve this problem by targeting the GADD45:MKK7 module medi-
ating NF-kB-induced survival of multiple myelomas.NF-kB transcription factors are activated
by numerous inflammatory stimuli and,
in turn, induce expression of cytokines,
chemokines, secondary inflammatory
mediators, and critical immune response
genes (Figure 1). Nearly 30 years ago,
NF-kB was found to suppress apoptotic
cell death and eventually was found to
inhibit necrosis as well (Lin and Karin,
2003). Subsequently, it was noted that
NF-kB is frequently activated in solid
and hematopoietic malignancies (Staudt,
2010), giving rise to the proposal that its
protumorigenic function depends on inhi-
bition of malignant cell death, induced
by either anticancer therapies or tumor
suppressor and surveillance mechanisms
(Karin et al., 2002). The logical extension
of this hypothesis, which is supported
by vast experimental evidence, was that
inhibitors of NF-kB activity or activation
should be effective either as a stand-
alone treatment or in combination with
chemotherapy or radiation therapy in
malignancies in which NF-kB is activated
by microenvironmental stimuli or genetic
changes result in treatment resistance.
Not surprisingly, this hypothesis
kindled an intense race to develop NF-kB inhibitors, most often by targeting IkB
kinase (IKKb), a protein kinase that is
essential for NF-kB activation (DiDonato
et al., 2012). However, when such inhi-
bitors were eventually tested either in
experimental animals or in human volun-
teers, they were found to have several
undesired side effects, including inflam-
mation, immune deficiencies, and liver
damage. Whereas immune deficiencies
and liver damage were anticipated from
the study of knockout mice and reflect
the important role of NF-kB in immunity
and tissuemaintenance, the inflammatory
effect of NF-kB inhibition, observed in
both mice and human, was rather
surprising. It was found to be due, in
part, to a novel function of NF-kB in
restraining the activation of caspase 1,
the enzyme responsible for secretion of
mature IL-1b by activated macrophages
(Greten et al., 2007). Such findings
brought the clinical development of IKKb/
NF-kB inhibitors to a halt. Approaching
NF-kB inhibition from an entirely different
direction, Tornatore et al. (2014; this issue
of Cancer Cell) seem to have found
a clever and practical solution to this
problem.NF-kB mediates its survival function,
in part, by preventing the activation of
the pro-apoptotic protein kinase JNK
(De Smaele et al., 2001; Tang et al.,
2001). In certain cell lines, the mediator
through which NF-kB curtails JNK acti-
vation is the stress-induced protein
GADD45b, which interacts with the JNK-
activating kinase MKK7 and blocks its
catalytic activity (Papa et al., 2004)
(Figure 1). However, it was not entirely
clear whether GADD45b is used by NF-
kB to inhibit cell death in all types of cells
or only in cancer cells. The finding that
GADD45b-deficient mice are relatively
healthy and die of old age (Lu et al.,
2004), unlike mice lacking IKKb or RelA
that die during late embryogenesis due
to liver damage (DiDonato et al., 2012;
Lin and Karin, 2003), suggested that
GADD45b is not essential for the survival
of most normal cells. To investigate its
importance in the survival of malignant
cells, Tornatore et al. (2014) surveyed
GADD45b expression in various cancers
and found it to be highly elevated in a sub-
set of multiple myelomas (MMs), tumors
derived from plasma cells (PCs) that
are frequently associated with mutations, October 13, 2014 ª2014 Elsevier Inc. 447
Figure 1. NF-kB-Dependent Cancer Cell Survival and Its Pharmacological Inhibition
NF-kB transcription factors are kept in the cytosol by specific inhibitors (IkB). Upon activation of IkB
kinases (IKK), NF-kB proteins enter the nucleus, bind DNA (parallel green lines), and activate transcription
of numerous genes encoding chemokines, cytokines, enzymes that produce secondary inflammatory
mediators (e.g., Cox2 and iNOS), inhibitors of inflammasome activation (question mark), and inhibitors
of apoptosis and GADD45b. The latter binds MKK7 and inhibits its ability to activate the proapoptotic
JNK protein kinases. Because IKK and NF-kB activation protect cancer cells from apoptosis, IKK inhibi-
tors were considered for cancer treatment. But their use blocks all NF-kB-dependent functions and can
result in inflammation and immune deficiencies. Proteasome inhibitors (bortezomib) also inhibit NF-kB
activation, although their therapeutic effect in multiple myeloma (MM) depends on another mechanism.
To overcome the complications of general NF-kB inhibition, Tornatore et al. (2014) developed DTP3, which
induces the death of multiple myeloma cells that express high amounts of GADD45b by preventing the
inhibition of MKK7 and allowing JNK activation to proceed. Inhibitors of NF-kB activation and NF-kB-
dependent cell survival are marked by the red boxes.
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(Staudt, 2010). Because its presence
and progression can be easily monitored
through blood tests, MM has served as
a popular proving ground for the develop-
ment of anticancer drugs, including the
proteasome inhibitor bortezomib (Val-
cade). Although bortezomib can inhibit
NF-kB activity, its therapeutic mode of
action in MM is NF-kB independent.
Analysis of monoclonal PC isolated
from MM patients and MM cell lines
demonstrated that GADD45b expression
is elevated in at least 50% of them and
that the silencing of GADD45b or RelA
in six MM cell lines chosen for high
GADD45b expression results in sponta-
neous cell death. Importantly, cell death
depends on MKK7-mediated JNK acti-
vation, suggesting that a molecule that
interferes with the ability of GADD45b to
block MKK7 activity would function as a
specific inhibitor of GADD45b-mediated448 Cancer Cell 26, October 13, 2014 ª2014cell survival. To accomplish this goal, Tor-
natore et al. (2014) followed a road rarely
taken by drug developers and chose to
develop inhibitors of the GADD45b:MKK7
interaction. By screening a combinatorial
library of L-tetrapeptides and lead optimi-
zation, they identified two acetylated (Ac)
L-tetrapeptides, Ac-LTP1 and Ac-LTP2,
that blocked the GADD45b:MKK7 inter-
action at a very low concentration.
Surprisingly, the D-enantiomers of both
peptides, Ac-DTP1 and Ac-DTP2, were
as active as the parental compounds,
with the added advantage of being resis-
tant to serum proteases. Further improve-
ment, mainly geared to increase bioavail-
ability, resulted in development of DTP3,
which binds to MKK7 and prevents its in-
hibition by GADD45b (Figure 1). Although
DTP3 is not a rigid molecule, it binds to
MKK7 with surprisingly high affinity (Kd =
65 nM) and selectivity, leading to JNK
activation and spontaneous killing ofElsevier Inc.high GADD45b-expressing MM cell lines
at rather low concentrations. DTP3 also
exhibited remarkable potency against
primary PCs isolated from MM patients
and, unlike bortezomib, hardly exhibited
cytotoxicity against normal PC, resulting
in a high therapeutic index. Remarkably,
the cytotoxic effect of DTP3 was even
more pronounced than that of IKKb
inhibitors, suggesting that canonical
IKKb-dependent NF-kB signaling may
not be the only inducer of GADD45b
expression. Importantly, DTP3 com-
pletely blocked the growth of subcutane-
ously or orthotopically implanted MM cell
lines in mice as long as the treatment
was initiated when the tumors were quite
small (100–200 mm3).
Although mice treated for 8 weeks with
a rather high dose of DT3 (29 mg/kg/day)
were not found to exhibit any apparent
side effects, it may be too early to pop
the champagne. First, one would like to
see how effective DTP3 is against a high
load of advanced tumors that are more
reflective of the stage at which MM is de-
tected and treated in patients. Second,
one should be aware that not all side
effects of NF-kB inhibition are easily
apparent. Enhanced inflammasome acti-
vation in laboratory mice, which are kept
under barrier conditions, is only seen
upon challenge with inflammasome acti-
vators, and susceptibility to infections
is revealed only in the presence of
infectious bacteria. Although inhibition
of MKK7-mediated JNK activation by
GADD45bmay have no impact on inflam-
masome activity, the potentiation of JNK
activation in either MM cells or myeloid
cells could enhance the production of
tumor necrosis factor and other inflam-
matory cytokines. A third issue that needs
to be addressed is the development of
drug resistance. The current treatment
of MM is plagued by rapid appearance
of drug resistance; patients that respond
to one treatment regimen often need to
be placed on another regimen because
of drug resistance. Even a single mutation
in the MKK7 gene may disrupt DTP3
binding and upregulation of the JNK-acti-
vating kinase MKK4 may have a similar
effect.
Notwithstanding further evaluation of
its safety and therapeutic efficacy, the
development of DTP3 is a remarkable
achievement in basic cancer biology and
its translational application. One would
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Previewshave to eagerly wait for further studies
of DTP3 in other NF-kB-dependent hema-
tological malignancies and solid tumors
that overexpress GADD45b. Hopefully,
these studies will also pave the way for
the development of other approaches for
curtailing the survival activity of NF-kB in
GADD45b-negative cancers.
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In this issue of Cancer Cell, Yang et al. describe a causal relationship between gene body methylation and
gene expression and a role for genic methylation in response to clinical DNA methylation inhibitors, which
suggests that the mechanism of action of these inhibitors includes gene body hypomethylation-induced
downregulation of cancer-associated genes.DNA cytosine methylation is an ancient
regulatory mechanism present in diverse
phylogenies, including vertebrates, plants,
and some fungi (Jones, 2012). Cytosine
methylation of CG dinucleotides by DNA
methyltransferases (DNMTs) in promoters
is associated with gene silencing, e.g., in
X chromosome inactivation and imprinting
(Jones,2012),andpromoterhypermethyla-
tion is thought tocontribute to aberrant reg-
ulatory programs in cancer (Shenker and
Flanagan, 2012). Within the last decade,
so-called ‘‘epigenetic’’ drugs have come
to the forewith U.S. Food andDrug Admin-
istration approval of cytidine analog DNMT
inhibitors such as 5-aza-2-deoxycytidine
(5-Aza-CdR) formyelodysplasticsyndrome
and acute myeloid leukemia. Excitingly,
studies have also hinted at the efficacy of
this mode of intervention in solid tumors
(Shenker and Flanagan, 2012), expanding
the utility of these chemotherapeutics be-
yond hematologic malignancies.Although promoter methylation, which
maintains a ‘‘closed’’ chromatin state that
impairs transcriptional initiation (Jones,
2012), has beenwell studied, less is known
about the role of methylation in gene
bodies. Intriguingly, unlike at promoters
where methylation is associated with
gene repression, genicmethylation is posi-
tively correlated with gene expression
(Figure 1A) (Maunakea et al., 2010; Varley
et al., 2013). It is thought that DNA methyl-
ation inhibitors cause promoter hypome-
thylationandsubsequentgene reactivation
(Shenker and Flanagan, 2012). However,
the effect of these drugs on gene body
methylation has not been extensively
studied.
In this issue of Cancer Cell, the work
of Yang et al. (2014) suggests a
causal relationship between gene body
methylation and gene expression and
expands the understanding of the
mechanism of action of cytidine analogcancer chemotherapeutics. They as-
sayed genome-wide methylation at
various time points after short treatment
of a dividing colon cancer cell line with
5-Aza-CdR, allowing interrogation of re-
methylation kinetics and the durability
of methylation changes upon drug with-
drawal (Figure 1A). A clustering approach
used to classify genomic regions into
groups with high and low remethylation
rates revealed that gene bodies were
rapidly remethylated compared to pro-
moters (Figure 1B). Furthermore, gene
body remethylation was correlated with
gene expression. Exploiting DNMT
knockout cell lines, the authors deter-
mined that DNMT3B is required for rapid
remethylation of gene bodies following
5-Aza-CdR treatment (Figure 1A). Both
DNA methylation and gene expression
were attenuated in DNMT3B deficient
cells following 5-Aza-CdR treatment,
suggesting that DNMT inhibitor-induced, October 13, 2014 ª2014 Elsevier Inc. 449
